Boehringer Ingelheim and BaroFold announce strategic agreement
13 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and BaroFold, Inc, have entered into a non-exclusive technology and commercial license option agreement...
List view / Grid view
13 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and BaroFold, Inc, have entered into a non-exclusive technology and commercial license option agreement...
13 November 2012 | By Abbott
Details on its phase 3 hepatitis C registrational program...
13 November 2012 | By GlaxoSmithKline
24-week data from VIKING-3 Phase III study...
13 November 2012 | By AstraZeneca
Court in Germany has found the formulation patent protecting SEROQUEL XR® prolonged-release tablets to be invalid...
13 November 2012 | By Catalent Pharma Solutions
Deal follows study which achieved record yield for human alpha-1 antitrypsin (hAAT) molecule...
12 November 2012 | By Amgen
Amgen and Pfizer announced that results from several Enbrel® (etanercept) studies...
12 November 2012 | By Abbott
Results from a post-hoc analysis...
12 November 2012 | By AstraZeneca
AstraZeneca announced positive top-line results from two Phase III trials...
12 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Molecular Partners have entered into a strategic manufacturing collaboration...
12 November 2012 | By Novartis
New two-year results...
12 November 2012 | By Abbott
The first long-term patient-reported health outcomes data...
12 November 2012 | By Bristol-Myers Squibb Company
Phase III development anticipated to begin in 2014...
11 November 2012 | By Merck
Merck announced the presentation of early interim results...
11 November 2012 | By Novartis
New data from two Phase II trials of ACZ885...
10 November 2012 | By Boehringer Ingelheim
Pivotal Phase III interferon-free study being initiated following positive Phase IIb results...